Skip to main content
Livermore
Livermore
ZHEN

Vitruvian Partners LLP

SEC CIK
0001692590
Latest filing
Aug 10, 2026

The latest 13F from Vitruvian Partners LLP covers Q2 2026 (filed Aug 10, 2026): 8 long positions worth $89.7M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Hinge Health, Inc. (HNGE) at 46.9%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
1
Est. +$3.35M
Added
0
Reduced
3
Est. −$66.9M
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. HNGEHinge Health, Inc.
    46.9%$42.0MHistory
  2. XMTRXometry, Inc.
    19.5%$17.5MHistory
  3. CARGCarGurus, Inc.
    13.3%$11.9MHistory
  4. GLBEGlobal-E Online Ltd.
    8.1%$7.30MHistory
  5. MXCTMaxcyte, Inc.
    6.9%$6.20MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. WSEWise Group plc
    +$3.35MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. WSEWise Group plc
    +3.74 pp0.0% → 3.7%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. HNGEHinge Health, Inc.
    −$61.7MReducedHistory
  2. CARGCarGurus, Inc.
    −$4.19MReducedHistory
  3. XMTRXometry, Inc.
    −$1.04MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CARGCarGurus, Inc.
    −1.09 pp14.4% → 13.3%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$89.7M
−$22.2M (−19.8%) vs. prior quarter
Positions
8
+1 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
3.3%
Q2 2026, one quarter
Average holding period
9.8 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $2.45B (Q2 2021)

Q1 2021: $291.6MQ2 2021: $2.45BQ3 2021: $2.40BQ4 2021: $1.92BQ1 2022: $942.2MQ2 2022: $589.7MQ3 2022: $560.3MQ4 2022: $474.9MQ1 2023: $468.0MQ2 2023: $491.3MQ3 2023: $352.6MQ4 2023: $393.5MQ1 2024: $315.4MQ2 2024: $340.7MQ3 2024: $257.5MQ4 2024: $116.2MQ1 2025: $104.8MQ2 2025: $164.2MQ3 2025: $144.2MQ4 2025: $139.2MQ1 2026: $111.8MQ2 2026: $89.7M
Q1 2021Q2 2026
13F filings of Vitruvian Partners LLP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 10, 20268$89.7MHNGEXMTRCARGvs. Q1 2026SEC
Q1 2026May 11, 20267$111.8MHNGEMQCARGvs. Q4 2025SEC
Q4 2025Feb 6, 20267$139.2MHNGEMQCARGvs. Q3 2025SEC
Q3 2025Nov 10, 20257$144.2MHNGEMQCARGvs. Q2 2025SEC
Q2 2025Aug 11, 20257$164.2MHNGEMQCARGvs. Q1 2025SEC
Q1 2025May 8, 20256$104.8MMQCARGMXCTvs. Q4 2024SEC
Q4 2024Feb 11, 20256$116.2MMQCARGMXCTvs. Q3 2024SEC
Q3 2024Nov 12, 20246$257.5MGLBEMQCARGvs. Q2 2024SEC
Q2 2024Jul 18, 20248$340.7MGLBEWalkme LtdMQvs. Q1 2024SEC
Q1 2024May 14, 20248$315.4MGLBEMQWalkme Ltdvs. Q4 2023SEC
Q4 2023Feb 9, 20249$393.5MGLBEMQWalkme Ltdvs. Q3 2023SEC
Q3 2023Nov 13, 202310$352.6MGLBEMQWalkme Ltdvs. Q2 2023SEC
Q2 2023Aug 14, 20239$491.3MGLBEWalkme LtdMQvs. Q1 2023SEC
Q1 2023May 9, 20239$468.0MGLBEWalkme LtdMQvs. Q4 2022SEC
Q4 2022Jan 11, 20239$474.9MGLBEWalkme LtdMQvs. Q3 2022SEC
Q3 2022Oct 31, 20229$560.3MGLBEMQWalkme Ltdvs. Q2 2022SEC
Q2 2022Jul 14, 20228$589.7MGLBEMQWalkme Ltdvs. Q1 2022SEC
Q1 2022May 4, 20228$942.2MGLBEMQWalkme Ltdvs. Q4 2021SEC
Q4 2021Feb 11, 20228$1.92BGLBEMQFarfetch Ltdvs. Q3 2021SEC
Q3 2021Nov 15, 20217$2.40BGLBEMQFarfetch Ltdvs. Q2 2021SEC
Q2 2021Aug 13, 20216$2.45BGLBEMQFarfetch Ltdvs. Q1 2021SEC
Q1 2021May 17, 20214$291.6MFarfetch LtdINSEAPI–SEC

13D and 13G filings

Companies where Vitruvian Partners LLP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Vitruvian Partners LLP does not currently report owning 5% or more of any company.

Latest filings

6 filings on file made by Vitruvian Partners LLP or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Vitruvian Partners LLP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
WalkMe Ltd.Sep 16, 202413D/AOld format–––SEC
GLBEGlobal-E Online Ltd.Feb 9, 202413G/AOld format–––SEC
GLBEGlobal-E Online Ltd.Feb 10, 202313G/AOld format–––SEC
GLBEGlobal-E Online Ltd.Feb 11, 202213GOld format–New–SEC
WalkMe Ltd.Dec 17, 202113D/AOld format–––SEC
WalkMe Ltd.Jun 28, 20215:02 PM ET13DOld format–New–SEC